Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Withdrawn before enrolling

Conditions studied: Ovarian Cancer

In brief

Primary objective: To estimate the overall clinical response rate (CR, PR, SD) of weekly docetaxel and weekly topotecan in women with recurrent platinum resistant ovarian or primary peritoneal cancer. Secondary objectives: To access the safety and tolerability of this novel combination chemotherapy regimen of weekly docetaxel and weekly topotecan in women with recurrent platinum resistant ovarian or primary peritoneal cancer To estimate the progression free survival (PFS) and overall survival (OS) for women with recurrent platinum resistant ovarian or primary peritoneal cancer treated with this weekly docetaxel and weekly topotecan.

Key facts

Study ID

NCT00484666

Run by

Carilion Clinic

People needed

0

Starts

2006-05-01

Expected to finish

2009-05-01

Last updated by the study team

2019-09-16

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• All patients will have had histologically documented ovarian epithelial, fallopian tube or peritoneal cancer.
• Patients must have received one prior platinum- and paclitaxel based regimen
• Patients must be platinum-resistant defined as recurrence or progression of disease <6 months since previous treatment with a platinum based treatment regimen.
• Patients must not have received radiotherapy.
• Patients with the following histologic epithelial cell types are eligible:
• Serous Adenocarcinoma
• Endometrioid Adenocarcinoma
• Mucinous Adenocarcinoma
• Undifferentiated carcinoma
• Clear cell Adenocarcinoma
• Mixed epithelial carcinoma
• Transitional cell
• Malignant Brenner's tumor
• Adenocarcinoma NOS
• Patients may have measurable or evaluable disease whereas evaluable disease is defined as new onset pleural effusion, ascites or a rise in CA-125 level >2x institutions upper limit of normal x 2 now sooner than one week apart.
• Patients could not have more than two previous chemotherapeutic regimens for their advanced ovarian cancer.
• Patients must be at least 18 years of age
• Patients must have a serum creatinine < 1.5 mg/dl
• Patients must have adequate hematologic reserve (ANC > 1500/mm3, hemoglobin ≥ 9.0 gm/dL and platelets > 100,000/mm3)
• Patients must have adequate hepatocellular function:
• Total Bilirubin < institutional upper limits of normal (ULN), AST or ALT and Alkaline Phosphatase must be within the range allowing for eligibility
• Patients must have GOG performance status of 0, 1 or 2.
• Patients must a have signed, approved informed consent form on file.

You may not qualify if…

• Patients with borderline ovarian cancer.
• Patients with GOG performance status 3 or 4.
• Patients who have received prior topotecan and/or docetaxel.
• Patients who have a history of psychiatric illness or other concurrent severe and/or uncontrolled co-morbid medical condition that would preclude study completion (i.e., uncontrolled infection, hypertension, ischemic heart disease, myocardial infarction within 6 months, congestive heart failure).
• Patients with other invasive malignancies, with the exception of non-melanoma skin cancer or any evidence of the other cancer(s) present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy.
• Patients with a history of severe acute hypersensitivity reaction to medications formulated with polysorbate 80.
• Patients with baseline peripheral neuropathy ≥ Grade 2.
• No use of investigational drugs or alternative medicine anticancer therapy within the last 4 weeks of 1st dose of study drug.
• Pregnant or lactating women with reproductive potential. (All patients enrolled in this study will be postmenopausal or have undergone surgery that includes hysterectomy and oophorectomy that would render them unable to conceive children.)

Where it is running

• Carilion GYN Oncology Associates — Roanoke, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.